Drugs / Alpha-type-1 Polarized Dendritic Cells
Alpha-type-1 Polarized Dendritic Cells
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03735589 | Dec 2023 → Dec 2025 | fallopian tube cancer, primary peritoneal carcinoma, uterine adnexa cancer | Roswell Park Cancer Institute | Withdrawn | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT05539365 | Feb 2025 → Feb 2027 | female breast carcinoma, triple-negative breast carcinoma | Roswell Park Cancer Institute | Withdrawn | No outcome recorded |
| Phase 2 | NCT04093323 | Nov 2024 → Apr 2025 | — | Roswell Park Cancer Institute | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Alpha-type-1 Polarized Dendritic Cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05539365 ↗ |
| Modality | Cell therapy | “another population of "educated" immune cells” NCT03735589 ↗ |
| Route | Other | “Given ID” NCT03735589 ↗ |